Skip to main content

Featured

OAS Just Got Its Biggest Raise of 2026: What 1.4% Actually Pays

  Canadian Money Brief • Published October 2, 2026 Old Age Security is going up 1.4% for the October-to-December quarter, the biggest of the four quarterly adjustments in 2026. For a senior on the maximum pension, that works out to $10.53 more a month . Whether that feels like a raise or just a catch-up depends on a number most headlines skip: how much prices have risen over the past year. +$10.53 a month Maximum OAS for ages 65 to 74 goes from $751.97 to $762.50. That is about $126 more over a year, and it starts with the Oct. 28 deposit. What actually changes on October 28 The new rate applies to the Oct. 28 payment and the two after it (Nov. 26 and Dec. 22). Nothing needs to be filed. It applies to OAS, the Guaranteed Income Supplement (GIS) and the Allowances automatically. Maximum monthly amount Jul–Sep 2026 Oct–Dec 2026 Change OAS, ages 65 to 74 $751.97 $762.50 +$10.53 OAS, age 75 and over $827.17 $838.75 +$11.58 GIS, single senior (approx.) $1,123.17 about $1,138.89 about +$...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment